title: Use of phosphodiesterase-5 inhibitors by college students.
abstract: The objective of this study was to identify the use of phosphodiesterase type 5 inhibitors among university students from the city of Sao Paulo (SP) in Brazil. Male students (n=350) replied to a questionnaire about diagnosis of erectile dysfunction, the frequency and reason for the use of phosphodiesterase type 5 inhibitors, the specific medication used, whether their use was accompanied by a medical prescription and any reported side-effects. The results shows that a total of 53 (14.7%) students had already used this kind of medication without a prescription or medical diagnosis for erectile dysfunction, of which 53% reported using sildenafil, 37% tadalafil and 10% vardenafil. The main adverse side-effects reported were headache (23%) and flushing (10%) and the main reasons for using the inhibitor were curiosity (70%) and erectile improvement (12%).
authors.affiliation: Faculdade de Farmácia, Universidade Nove de Julho, São Paulo, Brasil.
authors.forename: Vanessa Mello de
authors.initials: VM
authors.lastname: Freitas
authors.forename: Fabiana Gatti de
authors.initials: FG
authors.lastname: Menezes
authors.forename: Michele Melo Silva
authors.initials: MM
authors.lastname: Antonialli
authors.forename: Jorge Willian Leandro
authors.initials: JW
authors.lastname: Nascimento
mesh_terms: D000293:Adolescent; D000328:Adult; D001938:Brazil; D002243:Carbolines / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D012651:Self Medication / Q000523:psychology / Q000706:statistics & numerical data*; D000068677:Sildenafil Citrate; D013334:Students / Q000523:psychology / Q000706:statistics & numerical data*; D013450:Sulfones / Q000627:therapeutic use; D000068581:Tadalafil; D014227:Triazines / Q000627:therapeutic use; D000069058:Vardenafil Dihydrochloride; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D002243:Carbolines; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D014665:Vasodilator Agents; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate